Drug discovery in renal disease--towards a more efficient framework

Area of Science:

• Pharmacology and Drug Development
• Renal Disease Research
• Regulatory Science

Background:

• Drug development is hampered by significant time and cost, particularly for renal diseases.
• Efficient drug research necessitates understanding disease pathophysiology, target validation, and drug discovery strategies.
• Academic drug development benefits from international networks and high-quality nonclinical data.

Purpose of the Study:

• To highlight the challenges in drug approval, especially for renal diseases.
• To emphasize the need for academics to understand pharmaceutical regulations and novel development strategies.
• To advocate for collaboration between researchers and regulatory authorities.

Main Methods:

• Review of existing drug development processes and challenges.
• Analysis of the requirements for academic-led drug development.
• Examination of the role of regulatory authorities in drug discovery and validation.

Main Results:

• Inefficiencies in drug development lead to delays and increased costs.
• A gap exists in academics' understanding of pharmaceutical regulations and advanced development strategies.
• Collaboration with regulatory bodies can optimize surrogate marker validation and drug efficacy.

Conclusions:

• Enhanced collaboration between academia and regulatory authorities is essential for efficient drug development.
• Understanding pharmaceutical practices and utilizing novel strategies can accelerate the approval of new drugs.
• The Japanese framework offers a model for fostering such productive collaborations.